Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Oct 27;30(43):14502–14512. doi: 10.1523/JNEUROSCI.3909-10.2010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 the authors 0270-6474/10/3014502-11$15.00/0

PMC Copyright notice

Figure 7. — Application of GDNF into the VTA causes a rapid and sustained elevation of DA overflow in the NAc that is blocked by inhibition of the MAPK pathway. A, Left, Time course of dialysate concentrations of DA from the NAc before and after intra-VTA infusion of 10 μg/μl per side (filled circles) or vehicle (Veh; open circles). Two-way ANOVA (treatment × fractions) shows a significant effect of treatment (F_(1,156) = 9.40; p < 0.01) and fraction (F_(13,159) = 4.88; p < 0.001) and a significant interaction between both factors (F_(13,159) = 2.75; p < 0.01). Post hoc analysis using the method of contrasts shows a significant difference between the vehicle and the GDNF conditions from fractions 5 to 14 (T > 1.81; p < 0.05). The basal concentration of DA in dialysate was 1.97 ± 0.53 and 2.14 ± 0.42 nm for the Veh and GDNF groups, respectively. Right, Bar graph comparing the DA levels in the NAc after GDNF or vehicle injections into the VTA. The values were averaged from fractions 5 to 8. n = 8 (Veh) and n = 6 (GDNF). B, Left, MEK inhibitor U0126 (0.5 μg/μl per side) or vehicle were infused in the VTA 1 h before the application of GDNF (10 μg/μl per side) or vehicle. The time course of dialysate concentrations of DA from the NAc before and after intra-VTA infusion of GDNF (filled circles) or GDNF/U0126 (open circles) is shown. Two-way ANOVA (treatment × fractions) shows a significant effect of treatment (F_(1,156) = 8.35; p < 0.01) and fraction (F_(13,159) = 4.03; p < 0.001) and no interaction between both factors (F_(13,159) = 1.86; p = 0.12). Post hoc analysis using the method of contrasts shows a significant difference between the Veh/GDNF and the U0126/GDNF conditions from fractions 11, 12, 15, and 17 (t > 1.68; p < 0.05). The basal concentration of DA in dialysate was 0.75 ± 0.18 and 1.13 ± 0.15 nm for the Veh/GDNF and U0126/GDNF groups, respectively. Right, Bar graph comparing the DA levels in the NAc after vehicle, U0126, or GDNF injections into the VTA. The values were averaged from fractions 5 to 8 for the vehicle and U0126 injections and from fractions 9 to 12 for the GDNF injections. n = 6 (Veh/GDNF) and n = 8 (U0129/GDNF). In A and B, intra-VTA infusion of 75 ng of baclofen confirmed the functional connection between the VTA and NAc placements by reducing NAc DA overflow in the four groups. *p < 0.05; **p < 0.01.